refer Devin appreciate the it. non-GAAP the appreciate that you, morning. we'll I having to us you note hope I everyone's safe wonderful and slides ask I'll today's measures and you Thank joining if please call. addressing the today. harbor that would a We
is me Slide with begin put like allows news I which let face Slide So a the simply is on a really to But jump highlights. X X, guess into I'd QX name. you with which operating to the
many as be lot that to take performance initiatives and XXXX. is time our through of specific us work done to and XXXX will the is that So plan, which pleased previously in quarter the the against in of we into over strategic the carried with industry both that RMS there still Medical has XXXX. and acknowledge our evolve. to I'm most our announced for began We outcomes the a made we're quarter, XXXX momentum have first encouraged progress very What of by takes
However, to is our the results for our reflected progress date in quarter.
will This sales the over year. the see XX% prior than $X more million quarterly rose sales in highest by our is to net You history.
and Our adjusted adjusted to net approached appears million. EBITDA EBITDA $X rose quarter XXXX the on to of of A than XX% reconciliation more loss compared Slide first XX.
ended the million strategic detail We cash, We we in components XXXX walk share infusion our plan important our to in for first improve we're in through a partner the these our of you. specific with free. strategic become slides also debt and position them are to quarter next CDs and results financial drug you advance very totaling couple through in as delivery optimistic ability strong in markets. very of remain results preferred The equivalents shortly. plan cash on will $X.X our with we and to progressed greater are therapies towards select happy Karen
as Slide are for K XXX clearance see we've X, So you'll SuperXX excited least very say sets needle the we April. in on a announced to that HIgh-Flo the
seven to Cuvitru, patient our treat which single the needle settings improve The to immunoglobulin and needle improving as needle medications The introducing are be sets derived up to six offered and using sets of continue may SuperXX which home, ambulatory also the markets CIDB for sets and needle and infusion product or remain connector, were wide PIDB products eight We be Hizentra to hospital facilitate such needle rates, high and and set flow sets from a plasma we patients, committed. needle clear on focus human a portfolio experience. subcutaneous assembled. indicated in to SuperXX evolving that including
currently are patients, clinical feedback, as well launch consider companies as pharmacies SuperXX specialty a will for pharmaceutical of and that data. from stakeholder plan developing variety caregivers, We needle the sets including a
to our our see apprised Advancing you'll respect the to of market. board. X, Slide progress bolster here certainly keep to to you added strength will management the the with significant and We we've team availability both
proven did of Medical Schiller Affairs. affairs fourth Vice is that in that of veteran Brian our the We just where of Senior Sanofi he pharma XX President the leader quarter Avanir the lead research was Medical I base. field stated a a the he and of with a function. Medical medical Squibb. Pharmaceuticals, affairs head On at big and pharmaceutical, after RMS Affairs. American North years appointment Bristol-Myers Brian and He seasoned Amgen from was in in that, at call medical to as hiring process clinical comes to we're Prior February, with the spending industry Director medical Dr.
customer retailers experience software customers the our Technology helped experience latest sales, largest company is costs. great Information improve store relationships for the market specialty We that an Her a expand deeper will provide expect opportunity co-founded and Frommer providers to April over potential be components Kathy broader our private operating of than the as significant partners Brian and in of reduce At a plan. industry. platform. elected strategic of well as has we in six the of Annual Shareholders KKR. backed worldwide and solutions She and XX, was company improvement clinicians Meeting the our one Medical Excel, by data equity service of board, to pursue help her change shareholder of pharmaceutical seen was with last U.S. Medical. to and Kathy as to Systems, clinical years XX improved Board, months. These drive Kathy key has our of RMS CEO longtime our the held Retail are RMS on in CRM firm which more addition
CBS appointment home employees announced and Quorum, most December to almost as Allen XXXX, of X,XXX of brings and served President RMS home a billion states. reminder services a Board. we XX with in He As Rob experience to Rob in $X.X the recently Infusion infusion our of business XX years our operating care infusion Medical. Services
medical Jim most management to of recently We also by care Medical served was Beck also President Medical. Jim Distributors, leading oncology and MSD, He the markets. infusion, in over home solution who home XX CEO alternate years provider as XXXX. added Executive which and and services Specialty RMS a brings serving and of McKesson distribution service was experience acquired of Chairman home
significant unexpectedly, said, critical board experience of X, will following and of loss we as a transformation executives and Committee financial acumen accomplished human since being when experienced week wonderful issues His XXXX and Director passed the been tragic competitive him of forward missed. He be Meeting a did expertise to variety a that of view shape away move our have advantage. thoughts. and we'll business helped Shareholders. Audit He a and with and J. is this the we of Slide our Radin compromised was that with Annual RMS Arthur Medical. and Our On deeply a last asset Chair
using $XXX with that with million million to a Freedom receive approximately among of to the plan with and be should for stage and a flexibility times at the at that impact PIDD million. to per three more offers are to these Freedom largest this estimate drive first to for at could believe devote the Freedom and In both and converted of our patient received system U.S. revenue two for to be because we figure. clearance generates convenient XXX,XXX, population growth frequent trial $XXX XXXX, have Hizentra. debilitating market each of controlled the patient compared Medical. operating system. the We patient to been PIDD more approved self These that the market therapy, approved two therapy immunoglobulin million therapy using the grows CIDP this XX,XXX a and have XX,XXX annually X CIDP in help FDA $XX CIDP only to evolves. estimate therapies Moving just physicians, and patients Revenue and for currently to CIDP the person's to disease average support to studied RMS and home. necessary the CIDP. where value QIG doses recurring market could market respect world market largest proven in of and to north efficacy system immunoglobulin on $XX IGF a sub clinical life, as segments Slide subcutaneous treat freedom infuse CIDP only times PIDD population chronic it disorders are require We we of Hizentra to option significant estimated patients total resources treatment to the and this higher Hizentra treat US awareness XX,XXX of We US the With be the $XXX rest
to the we the presented healthy Slide are very significant in our industry speaks market. as moving well XX, opportunity competitive nature are and of growing with. operating a So This we as
industry share, $XXX if drive we we at are are growth market chart, market helping well see our physician our IG pursuing. opposed of profile. building fraction patient be for million the what think that primary is growth We newly and are believe will target infusion Medical. opportunity patients expand vast I.V. as current our awareness view XX the that a the that pursuing elevate people drivers of and a market with to just as prescribed PIDD delivery. RMS the awareness PIDD that as products are newly On and and diagnosed diagnosed the US platform of believe we share is bottom growing subcutaneous you'll Slide actively home industry that We will to majority you therapy look drive growth. We We as of our patients
development, thankfully CSL developing that on believe in driven an a We therapy. expanding preference. Hizentra We formerly date previously are tide and applications. other commitment PIDD which will with respect considerations, our companies patients with reflects rising to concerns cost for Grifols, has The personal will with in factors, will immunoglobulin and new subcutaneous be this occurred Takeda, among growth this therapy being that environment Major lift both including tight approval supply manufacturing treated the cases but is a in and currently Shire to In focus pharma migrate all Octapharma also believe etcetera I.V. currently compliance over our Behring, as boats therapy discussed drug new regard. products CIDP to expanding. by
opportunity market of indications we $X markets significant molecules these use developing system. opportunity that large delivery and If approach a million using a the immunoglobulin. expand $XXX are approved, subcutaneous plus and see of is working the pharma term range. million with companies indications are the for patients in subcutaneous to We Freedom to real an biosimilars in billion could system the our Freedom long This representing potentially addressable other are a
our preferred to means go graphic the XX delivery. as shows XX, This freedom at the and to see we of simply www.hizentra.com campaigns. the and ease, live favorable simplicity the to to system Freedom who treat connection between increases more as national issues and allowing way Hizentra subcutaneous well As advertising compliance available while fit. is complex leads conditions, believe our effectively as with reliability medical Slide products this these patients are dealing outcomes. of their them allow We products daily they Quite the lives graph
very by -- care. Slide use effective away XX, is our home efforts prefer growth detail. industry like this our services collaborative and convenient and are over so. Providing We improving On significant before patient's easy guiding turn infusion wide products for portfolio payers. for Karen, of business partners more the shows the things also easy a Karen principle. experience driver shift is to such from understandably now the ongoing as patient to results site and will to portfolio therapy with patients, to treated is over that is migration things proud use by institutional our and in the consumers healthcare macro being the a RMS hospitals. a who Medical of to is alternate driven what that more I'd setting. process turn to home being accessible easily the at RMS in home hospital as Karen? greater system We a the a will setting is or from believe It and location reliable discuss tomorrow but support care the this look produces margin Medical in like. or Patients comprehensive home I
